,4 Targeted therapies are licensed for NSCLC (EGFR, ALK, ROS1 indications) and CRC (KRAS wild-type), but KRAS-mutated cancer remains an area of unmet clinical need. This evidence concerns the gene EGFR and colorectal carcinoma.